A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment

Inclusion Criteria

• •Male or female, aged between 12 and 17 years at the baseline visit
• •Patients with AD who have been prescribed dupilumab according to Agenzia Italiana del Farmaco (AIFA) reimbursement criteria and fulfilling the following criteria:
• •Patients with EASI\<16 and
• •1. Children's Dermatology Life Quality Index (CDLQI) ≥ 10 or
• •2. Peak Pruritus Numerical Rating Scale (PP-NRS) ≥ 7 or
• •3. localization in visible or sensitive areas (head/neck/hands or genitals)
• •* Patients able to understand and complete study-related questionnaires
• •* Provided signed informed consent or parental/legally acceptable representative consent and patient assent where applicable